FDA submission for Emergency Use Authorisation
Fri, 02 Jul 2021 11:16:00 GMT
Omega announces that following completion of the of US performance studies, its technology partner, Mologic Ltd has filed its submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorisation for its rapid point-of-care COVID-19 antigen test, for use under both the Omega’s VISITECT® brand and Global Access Diagnostics (GAD) brand.
Read the full RNS here
Comments are closed for this post, but if you have spotted an error or have additional info that you think should be in this post, feel free to contact us.